A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis

Acute-on-chronic liver failure (ACLF) is a severe condition characterised by multiorgan failure and high short-term mortality in hospitalised patients experiencing acute decompensation of cirrhosis.^1,2 While the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) criteria have been widely adopted for both diagnosis and prognostication, ongoing advancements in understanding organ dysfunction and the emergence of new therapeutic approaches necessitate updated, more precise criteria.^1,2 The objective of this research was to develop and validate the A-TANGO organ failure (OF) score, with the aim of refining ACLF diagnosis and improving its applicability for evaluating treatment response and stratifying patient risk.^1,2

Development and Validation of the A-TANGO Score

The A-TANGO organ failure (OF) score was developed and validated through a comprehensive process involving global cohorts.^1,2 The primary goal was to create a diagnostic and prognostic tool that offers enhanced accuracy for ACLF, particularly in light of evolving definitions of organ dysfunction and the availability of new therapies.^1,2 The development process focused on tailoring criteria to improve diagnostic precision, facilitate the assessment of treatment efficacy, and enhance risk stratification capabilities within clinical trials and practice.^1,2

The validation of the A-TANGO score involved assessing its performance against existing diagnostic criteria, specifically the EASL-CLIF criteria.^1,2 The research aimed to demonstrate that the A-TANGO score could provide a more refined diagnosis of ACLF, leading to improved prognostication for hospitalised patients with acute decompensation of cirrhosis.^1,2 The utility of the score extends to its potential for more accurate evaluation of patient response to interventions and for better categorising patients based on their risk of short-term mortality.^1,2

ACLF represents a distinct clinical entity from acute decompensation of cirrhosis, marked by a rapid deterioration of liver function and the development of extrahepatic organ failures. The pathophysiology involves systemic inflammation, immune dysfunction, and circulatory alterations, which contribute to the progression of organ damage. Early and accurate diagnosis of ACLF is critical for timely intervention, as delayed recognition is associated with significantly worse outcomes. Current management strategies often involve supportive care, treatment of precipitating factors, and in select cases, liver transplantation. The development of new diagnostic tools like A-TANGO is crucial for identifying patients who may benefit most from specific therapies and for guiding resource allocation in critical care settings. The global incidence of ACLF is substantial, with varying prevalence depending on geographical region and underlying etiologies of cirrhosis, such as alcohol-related liver disease, viral hepatitis, and non-alcoholic fatty liver disease. Improved diagnostic precision can therefore have a significant impact on public health worldwide.

In a related but distinct area, the European Association for the Study of the Liver (EASL) algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) has been adopted and validated in low-resource South Asian settings.³ This initiative highlights the broader effort within hepatology to improve diagnostic accuracy and accessibility for various liver conditions, including those that can progress to cirrhosis and potentially ACLF.³ While not directly part of the A-TANGO score development, the validation of noninvasive fibrosis algorithms underscores the importance of accurate and accessible diagnostic tools in managing advanced chronic liver disease globally.³

Limitations and Future Directions

The abstracts provided indicate that the A-TANGO score was developed and validated in global cohorts, suggesting a broad applicability.^1,2 However, specific details regarding the size, diversity, and characteristics of these cohorts, as well as the precise methodology of the validation, are not detailed in the abstracts.^1,2 Further investigation into the full papers would be necessary to understand the exact components of the A-TANGO score, its specific performance metrics (e.g., sensitivity, specificity, predictive values), and how it directly compares to the EASL-CLIF criteria in terms of clinical outcomes.^1,2 The abstracts state the aim to improve diagnostic accuracy, treatment assessment, and applicability in clinical trials, but the extent to which these aims were met with quantifiable results remains to be fully elucidated.^1,2 Future research will likely focus on prospective validation in diverse clinical settings and integration into clinical decision-making algorithms to assess its real-world impact on patient management and outcomes.

A key limitation of any new scoring system is its generalizability across different patient populations and healthcare systems. While the mention of "global cohorts" is promising, the specific demographic, etiological, and clinical characteristics of these cohorts are critical for assessing the score's external validity. For instance, the prevalence of specific organ failures or the response to standard therapies may differ significantly between regions with high rates of alcohol-related cirrhosis versus those with predominant viral hepatitis. Furthermore, the practical implementation of the A-TANGO score in resource-limited settings, where access to advanced diagnostics may be restricted, warrants careful consideration. The operational definitions of organ failure within the A-TANGO score, and how they align with or diverge from existing criteria, will also influence its clinical utility and comparability. Future studies should also explore the cost-effectiveness of implementing the A-TANGO score in routine clinical practice and its potential to reduce healthcare burdens associated with ACLF.